Sep. 1, 2014
On September 1, 2014, the Belgian company Ablynx announced that it has expanded its existing relationship with the Chinese firm Eddingpharm by granting it an exclusive, royalty- bearing license to develop and commercialise Ablynx’s anti-TNFα Nanobody®, ozoralizumab (ATN-103), in Greater China for all indications, including rheumatoid arthritis (RA).
Under the terms of the agreement, Eddingpharm will be responsible for the product's clinical development, registration and commercialization in Greater China. Ablynx will have access to the clinical data generated by Eddingpharm to support potential licensing discussions in other geographic regions.
Ablynx will receive an upfront payment of €2 million, payable in two tranches, and is entitled to receive development and commercial milestone payments plus tiered, double-digit royalties of up to 20%, based on annual net sales of ozoralizumab generated by Eddingpharm in Greater China.